Evotec has entered a definitive agreement to acquire Just Biotherapeutics and its in-house drug development technology platform J.DESIGN.

Just Biotherapeutics provides machine-learning technologies to design, develop and manufacture biologics. The company employes 90 people at its discovery, development and manufacturing facility in Seattle, Washington, US.

The transaction value of the deal is up to $90m, including potential performance-based earn-out components projected within the next three years. Evotec expects the acquisition to offer opportunities to further drive its long-term business strategy.

Evotec provides drug discovery and development services for small molecules. The deal will expand its offering to biologics in various therapeutic areas such as oncology, the central nervous system (CNS), pain, inflammation, metabolics and infectious diseases.

Evotec CEO Werner Lanthaler said: “Broadening our platform into biologics has always been key to our strategy. With this acquisition, we finally found the perfect match to complement our leadership in small molecules.”

Just Biotherapeutics’ J.MDTM technology leverages a machine-learning, computer-aided design tool to predict optimal molecules for further development. The platform comprises lab and computational tools to develop manufacturing processes and a current good manufacturing practice (cGMP) early clinical manufacturing facility. J.POD technology is designed to enable large-scale production of clinical and commercial-stage biologics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Broadening our platform into biologics has always been key to our strategy.”

Just Biotherapeutics CEO James Thomas said: “Combining Just.Bio with Evotec creates a technological powerhouse that will fuel our long-term mission to make important biologics accessible to patients worldwide.”

The acquisition is set to complete in Q2 2019.

In March this year, Evotec partnered with Swiss non-profit The Global Antibiotic Research and Development Partnership (GARDP) to discover new antibiotics to address the growing threat of antimicrobial resistance (AMR).